China approves Eli Lilly's GLP-1 weight-loss pill, giving it lead over Novo - report
jetcityimage
Eli Lilly (LLY) has secured Chinese regulatory approval for its oral GLP-1 weight-loss drug, orforglipron, becoming the first drugmaker to receive clearance for a GLP-1 weight-loss pill in the country, Reuters reported, citing China's medicine regulator.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.